Skip To Main Content
Hans Lee on Muck Rack

Hans Lee

  • Senior Finance Writer, Betashares
Manila, Sydney
As seen in: LinkedIn, MSN, MSN Australia, Bloomberg News, Daily Mail, Reuters, Wiley Online Library, Yahoo Singapore, Soundcloud, U.S. News and World Report and
Covers:  Business News (specialising in economics reporting), Politics, National and International Affairs

Get in touch with Hans

Contact Hans, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Hans Lee’s Biography

Read Full Bio →

Hans Lee is a student broadcaster and journalist, based out of Sydney, Australia. He was most recently a researcher and reporter for The Australian. Before that, he worked at Bloomberg News as the 2018 Sydney intern and at 2SER Radio as an anchor, producer and reporter.

Hans' passion for current affairs comes down to a global mindset and the aim to tell the whole story. His track record of hard news articles, sharp comment and multimedia experience is unrivalled for his age. He defines himself …

Hans Lee’s Journalist Portfolio

See all →
What Matters: Premiere

What Matters: Premiere

The show that started it all! Show 1! This week: Barnaby Joyce, the Lunar New Year and Company Taxes take cen…

View article →
Catalonia Report: On the Money

Catalonia Report: On the Money

This week, a special look into how Catalan is changing the world - and your pocketbook. Special Guest: Tim Ha…

View article →
Hans Moderates: Australia-China Special

Hans Moderates: Australia-China Special

The trade relationship between Australia and China is a constant theme in global economics. Chinese investmen…

View article →
Live Interview: Rod Sims and the ACCC

Live Interview: Rod Sims and the ACCC

Hans was at the ACCC Policy Launch in Sydney - and filed this report for 2SER News and On the Money. It inclu…

View article →
Bloomberg: IBM Lands $740 Million Deal to Supply Data Security to Australia

Bloomberg: IBM Lands $740 Million Deal to Supply Data Security to Australia

International Business Machines Corp. has secured a A$1 billion ($740 million) agreement to become a central …

View article →
Bloomberg: A $365 Billion Fund Manager Bets on Smokers

Bloomberg: A $365 Billion Fund Manager Bets on Smokers

Grappling with where to spend that extra dollar as the bull run for U.S. equities rages on? Try some unloved …

View article →

Articles

Who Are The Key Candidates to Receive Subcutaneous Amivantamab for HNSCC?

|
By Hans Lee, Barbara Burtness, Russ Conroy
| ONCOLOGY journal Verified
The rationale for excluding patients with HPV-positive oropharyngeal cancer and prior anti-EGFR exposure from cohort 1 of the phase 1b/2 OrigAMI-4 study (NCT06385080) highlights the strategic development of subcutaneous amivantamab-vmjw (Rybrevant Faspro) in recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
Open in Who Shared Issue with article?

Novel Cancer Vaccine Meets Primary, Secondary End Points in Resected Melanoma

|
By Hans Lee, Educating Patients, Crs RiskLaura Alder
| ONCOLOGY journal Verified
The primary end point of recurrence-free survival (RFS) and secondary end point of distant metastasis-free survival (DMFS) was met in the phase 3 INTerpath-001 trial (NCT05933577) assessing intismeran autogene (V940) plus pembrolizumab (Keytruda) for patients with completely resected stage IIB to IV melanoma, according to a press release from Merck.1 During the prespecified interim analysis, the combination showed a statistically significant and clinically meaningful improvement in RFS and...
Open in Who Shared Issue with article?

Addressing the Data Gap With Tarlatamab in Brain Metastatic SCLC

|
By Educating Patients, Crs RiskLaura Alder, Hans Lee
| ONCOLOGY journal Verified
At The 2026 Society of NeuroOncology (SNO) ASCO CNS Metastases Conference in Boston, MA, Laura Alder, MD, discussed a retrospective analysis she presented evaluating tarlatamab (Imdelltra) in patients with small cell lung cancer (SCLC) and brain metastases.1 More specifically, this population was largely excluded from the phase 3 DeLLphi-304 trial (NCT05740566)that supported the drug’s approval.
Open in Who Shared Issue with article?
See all 1,204 licensed articles (1,236 Total)